Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection

Journal of General Virology

Volumn 89, Issue 4, 2008, Pages 853-865

  Gerna, Giuseppe ^a   Sarasini, Antonella ^a   Patrone, Marco ^b   Percivalle, Elena ^a   Fiorina, Loretta ^a   Campanini, Giulia ^a   Gallina, Andrea ^b   Baldanti, Fausto ^a   Revello, M Grazia ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; PROTEIN PUL128; PROTEIN PUL130; PROTEIN PUL131A; VIRUS PROTEIN; ANTISERUM; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; FIBROBLAST; GENE LOCUS; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REACTIVATION; ANTIBODY SPECIFICITY; BLOOD; CELL CULTURE; CYTOMEGALOVIRUS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; SERODIAGNOSIS; UMBILICAL VEIN; VIROLOGY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; IMMUNE SERA; MIDDLE AGED; NEUTRALIZATION TESTS; ORGAN SPECIFICITY; UMBILICAL VEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 45549103019     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83523-0     Document Type: Article

References (39)

1. Adler, B., Scrivano, L., Ruzcics, Z., Rupp, B., Sinzger, C. & Koszinowski, U. H. (2006). Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87, 2451-2460.
2. Andreoni, K. A., Wang, X., Huong, S.-M. & Huang, E.-S. (2001). Human cytomegalovirus CMV-IGIV (CytoGam®) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure. Transplant Infect Dis 3, 25-30.
3. Bass, E. B., Powe, N. R., Goodman, S. N., Graziano, S. L., Griffiths, R. I., Kickler, T. S. & Wingard, J. R. (1993). Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 12, 273-282.
4. Boeckh, M., Bowden, R. A., Storer, B., Chao, N. J., Spielberger, R., Tierney, D., K., Gallez-Hawkins, G., Cunningham, T., Blume, K. G. & other authors (2001). Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7, 343-351.
5. Eggers, M., Metzger, C. & Enders, G. (1998). Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay. J Med Virol 56, 351-358.
6. Eggers, M., Bäder, U. & Enders, G. (2000). Combination of microneutralization and avidity assays: improved diagnosis of recent primary HCMV infection in single serum sample of second trimester pregnancy. J Med Virol 60, 324-330.
7. Eggers, M., Radsak, K., Enders, G. & Reschke, M. (2001). Use of recombinant antigens gB and g1l for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol 63, 135-142.
8. Fowler, K. B., Stagno, S. & Pass, R. F. (2003). Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289, 1008-1011.
9. Gerna, G., Revello, M. G., Percivalle, E., Zavattoni, M., Parea, M. & Battaglia, M. (1990). Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 28, 2681-2688.
10. Gerna, G., Revello, M. G, Percivalle, E. & Morini, F. (1992). Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenernia. J Clin Microbiol 30, 1232-1237.
11. Gerna, G., Zavattoni, M., Baldanti, F., Sarasini, A., Chezzi, L., Grossi, P. & Revello, M. G. (1998). Human cytomegalovirus leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 65, 1378-1385.
12. Gerna, G., Percivalle, E., Baldanti, F., Sozzani, S., Lanzarini, P., Genini, E., Lilleri, D. & Revello, M. G. (2000). Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74, 5629-5638.
13. Gerna, G., Percivalle, E., Sarasini, A., Baldanti, F., Campanini, G. & Revello, M. G. (2003). Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 84, 1431-1436.
14. + T cells. J Gen Virol 86, 275-284.
15. + T-cell immunity in patients receiving solid organ transplantation. AM J Transplant 6, 2356-2364.
16. Gerna, G., Sarasini, A., Genini, E., Percivalle, E. & Revello, M. G. (2006b). Prediction of endothelial cell tropism of human cytomegalovirus strains. J Clin Virol 35, 470-473.
17. Gianni, T., Forghieri, C. & Campadelli-Fiume, G. (2006). The herpesvirus glycoproteins B and H.L are sequentially recruited to the receptor-bound gD to effect membrane fusion at virus entry. Proc Natl Acad Sci U S A 103, 14572-14577.
18. Grossi, P., Minoli, L., Percivalle, E., Irish, W., Vigano, M. & Gerna, G. (1995). Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 59, 847-851.
19. Hahn, G., Khan, A., Baldanti, F., Koszinowski, U. H., Revello, M. G. & Gerna, G. (2002). The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 76, 9551-9555.
20. Hahn, G., Revello, M. G., Patrone, M., Percivalle, E., Campanini, G., Sarasini, A., Wagner, M., Gallina, A., Milanesi, G. & other authors (2004). Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78, 10023-10033.
21. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108, 1406-1412.
22. Messori, A., Rampazzo, R., Scroccaro, G. & Martin, N. (1994). Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation. A meta-analysis. Bone Marrow Transplant 13, 163-167.
23. Muñoz, I., Gutiérrez, A., Gimeno, C., Farga, A., Alberola, J., Solano, C., Prósper, F., García-Conde, J. & Navarro, D. (2001). Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J Med Virol 65, 77-84.
24. Nigro, G., Adler, S. P., La Torre, R., Best, A. M. & Congenital Cytomegalovirus Collaborating Group (2005). Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353, 1350-1362.
25. Patrone, M., Secchi, M., Fiorina, L., Ierardi, M., Milanesi, G. & Gallina, A. (2005). Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79, 8361-8373.
26. Patrone, M., Secchi, M., Bonaparte, E., Milanesi, G. & Gallina, A. (2007). Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 81, 11479-11488.
27. Quinnan, G. V., Jr, Kirmani, N., Rook, A. H., Manischewitz, J. R., Jackson, L., Moreschi, G., Santos, G. W., Saral, R. & Burns, W. H. (1982). Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 307, 7-13.
28. Reusser, P., Riddel, S. R., Meyers, J. D. & Greenberg, P. D. (1991). Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78, 1373-1380.
29. Revello, M. G. & Gerna, G. (2002). Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15, 680-715.
30. Revello, M. G., Percivalle, E., Arbustini, E., Pardi, R., Sozzani, S. & Gerna, G. (1998). In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 101, 2686-2692.
31. Revello, M. G., Baldanti, F., Percivalle, E., Sarasini, A., De-Gluli, L., Genini, E., Lilleri, D., Labò, N. & Gerna, G. (2001). In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 82, 1429-1438.
32. Ryckman, B. J., Rainish, B. L., Chase, M. C., Borton, J. A., Nelson, J. A., Jarvis, M. A. & Johnson, D. C. (2008). Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82, 60-70.
33. Schoppel, K., Schmidt, C., Einsele, H., Hebart, H. & Mach, M. (1998). Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 178, 1233-1243.
34. Sester, U., Gartner, B. C., Wilkens, H., Schwaab, B., Wossner, R., Kindermann, I., Girndt, M., Meyerhans, A., Mueller-Lantzsch, N. & other authors (2005). Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 5, 1483-1489.
35. Smith, M. G. (1956). Propagation in tissue cultures of cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc EXP Biol Med 92, 424-430.
36. Stagno, S., Pass, R. F., Cloud, G., Britt, W. J., Henderson, R. E., Walton, P. D., Veren, D. A., Page, F. & Alford, C. A. (1986). Primary cytomegalovirus infection in pregnancy. Incidence, transmission to the fetus and clinical outcome. JAMA 256, 1904-1908.
37. Subramanian, R. P. & Geraghty, R. J. (2007). Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proc Natl Acad Sci U S A 104, 2903-2908.
38. Wang, D. & Shenk, T. (2005a). Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79, 10330-10338.
39. Wang, D. & Shenk, T. (2005b). Human cytomegalovirus virion protein complex required for endothelial and epithelial cell tropism. Proc Natl Acad Sci U S A, 102 18153-18158.